Immunization

• EMA approval · 2026-08-24
  EMA Authorised: Rotarix (human rotavirus, live attenuated) — GlaxoSmithKline Biologicals S.A.

  Rotarix (human rotavirus, live attenuated) by GlaxoSmithKline Biologicals S.A. has been authorised by the EMA for immunization against rotav…

• EMA withdrawal · 2019-04-02
  EMA Withdrawn: Silgard (human papillomavirus type 6 L1 protein;human papillomavirus type 11 L1 protein;human papillomavirus type 16 L1 protein;human papillomavirus type 18 L1 protein) — Merck Sharp Dohme Ltd

  EMA withdrawn the HPV vaccine Silgard (HPV 6/11/16/18 L1 proteins) from the market.

• CLINICAL_TRIALS trial_result · 2018-11-14
  Clinical Trial Update: 3 Adjuvated Reduced Dose IPV-Al SSI Vaccines and Non-adjuvated Full Dose IPV SSI, as Booster Vaccination to Adolescents [Phase 1, Phase 2]

  Clinical trial update for adjuvated reduced-dose IPV vaccines and non-adjuvated full-dose IPV as adolescent booster vaccines; Phase 1/Phase …

• EMA withdrawal · 2013-08-23
  EMA Lapsed: Infanrix Penta (Diphtheria toxoid;tetanus toxoid;Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin);poliovirus (inactivated) (type 1 (Mahoney strain), type 2 (MEF-1 strain), type 3 (Saukett strain));hepatitis B surface antigen) — GlaxoSmithKline Biologicals S.A.

  EMA status indicates Infanrix Penta is lapsed, with the product no longer active in this market.

• EMA withdrawal · 2011-06-30
  EMA Withdrawn: Humenza (split influenza virus, inactivated, containing antigen*: A/California/7/2009 (H1N1)v like strain (X-179A)*propagated in eggs.) — Sanofi Pasteur S.A.

  EMA has withdrawn the Humenza influenza vaccine from the market.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA withdrawal · 2008-09-10
  EMA Withdrawn: Quintanrix (Diphtheria toxoid;tetanus toxoid;inactivated Bordetella pertussis;hepatitis B surface antigen (rDNA);Haemophilus influenzae type b polysaccharide) — GlaxoSmithKline Biologicals S.A.

  Quintanrix has been withdrawn from the market by GlaxoSmithKline Biologicals S.A., with the status indicating withdrawal for its diphtheria,…